Company intelligence / Profile preview
Kexing Biopharm Co., Ltd.
Shenzhen, Guangdong, Chinakexing.com.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has several approved products in China including recombinant human growth hormone, recombinant human interleukin-2, and recombinant human interferon alpha-1b. Recent developments include FDA and NMPA approval for clinical trials of GB05 (Human Interferon α1b Inhalation Solution) for RSV infections, GB08 (long-acting growth hormone) for growth hormone deficiency, and GB18 (nanobody-Fc fusion) for cancer cachexia.
- Therapeutic areas
- OncologyEndocrinologyInfectious Diseases
- Modalities
- Recombinant proteinsNanobody-Fc fusion proteinsHormonesInterferonsInterleukinsBiological products
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Kexing Biopharm Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kexing Biopharm Co., Ltd..